News & Events
On Dec. 11, 2014, Bob Vince won the Impact Award for his development of the ground-breaking AIDS drug, Ziagen. At the ceremony, Made in Minnesota: Celebrating University Innovators, President Kaler awarded Prof. Vince with a trophy for his innovative work. This inaugural award was given by the Office of Vice President Research (OVPR).
In the video below Prof. Vince discusses his innovation.
Even though sun damage may be the furthest thing from your mind right now, don’t let the cool weather fool you. Irreversible skin damage can happen all year round and excessive exposure to the damaging ultraviolet (UV) rays of the sun can have many adverse effects. So, just wear sunscreen, right? Well, here’s the kicker.
University of Minnesota researchers have found that two cancer drugs combined in pill form can be used to fight HIV. The research, published Aug. 30, still has a long road ahead before the pill can be tested on humans — a road that will take years to travel. “The road is littered with the carcasses of failed drug treatments,” said Dr. Keith Henry, director of HIV research at the Hennepin County Medical Center.
Chemical weapons like anthrax, sarin, mustard and ricin often make headlines, but what about the threat of a terrorist attack unleashing cyanide?
Bob Vince can't be sure where his becoming a scientist began, but where it led changed the world. As the discoverer of carbovirs, the precursor to the AIDS drug Ziagen, Vince's contribution to humanity can't be underestimated.
Though its history is one fraught with lessons and lawsuits, the drug's legacy, in the end, is and will be one of human health and some mercy for millions afflicted with HIV/AIDS.
Cyanide is one of the deadliest poisons around. Your body can handle a little of it, but for larger exposures an antidote is necessary. Current antidotes can work, but they're slow. That could change, however, now that three researchers at the University of Minnesota's Center for Drug Design (Profs Steve Patterson, Robert Vince and Herbert Nagasawa) have synthesized Sulfanegen, a faster-acting antidote.
Based on research conducted at the Center for Drug Design (CDD), Sulfanegen, a treatment for cyanide poisoning, will be developed and marketed.